Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corporation on February 16, 2016, covering events occurring on February 10, 2016. The Company, incorporated in Delaware and headquartered in Boston, MA, operates in the biotechnology sector. The filing primarily addresses the execution of a material definitive agreement regarding equity issuance and provides historical context regarding the Company's 2014 reverse merger.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on capital structure adjustments and historical equity transactions.
- Equity Issuance: 1,260,255 shares of common stock issued to AFH Holding and Advisory, LLC.
- Historical Capitalization: Details provided on share counts exchanged during the September 2014 merger with Bone Biologics, Inc., including shares acquired via cash purchase and debt conversion by various shareholders.
Material Changes
The primary material change reported is the issuance of 1,260,255 shares to AFH Holding and Advisory, LLC ("AFH"). This issuance fulfills a "Share Adjustment" provision from a Letter of Intent dated May 6, 2014. Under the original agreement, AFH was entitled to 10% of the Company's outstanding shares on a fully diluted basis following an anticipated private placement (PIPE) of $8 million to $10 million. The Company recognized that subsequent issuances had diluted AFH's interest and agreed to issue these shares to restore the intended ownership percentage.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future operations. The transaction was executed under Section 4(a)(2) of the Securities Act of 1933 as a private placement to an accredited investor, avoiding public offering registration requirements. No specific risks or contingencies were disclosed beyond the standard implications of equity dilution inherent in the share adjustment.
Investor Verification Checklist
- Verify the current fully diluted share count to confirm AFH's post-issuance ownership percentage aligns with the 10% target.
- Review the status of the anticipated $8 million to $10 million PIPE financing referenced in the 2014 Letter of Intent.
- Confirm the accreditation status of AFH Holding and Advisory, LLC as required for the Section 4(a)(2) exemption.
- Examine the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.